<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="31348">Capecitabine</z:chebi> is a member of the fluoropyrimidine family of chemotherapeutic agents that selectively delivers <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> (5-FU) to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>It is increasingly used as part of combined modality treatment for gastrointestinal <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Cardiotoxicity has been documented to occur with 5-FU, but due to an expansion in <z:chebi fb="0" ids="31348">capecitabine</z:chebi> use, reports exist of its propensity to <z:e sem="disease" ids="C0010073" disease_type="Disease or Syndrome" abbrv="">coronary vasospasm</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>We report the case of a 28-year-old man, with no preceding <z:mp ids='MP_0006112'>angina</z:mp>, presenting with a reversible episode of <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>) at rest in his fifth course of <z:chebi fb="0" ids="31348">capecitabine</z:chebi> chemotherapy for <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Emergency resuscitation successfully restored spontaneous circulation, with initial ST segment elevation in the inferolateral leads on electrocardiogram prompting emergency coronary angiography </plain></SENT>
<SENT sid="5" pm="."><plain>This demonstrated <z:mpath ids='MPATH_458'>normal</z:mpath> coronary arteries </plain></SENT>
<SENT sid="6" pm="."><plain>ST segments normalized post-angiography and the patient rapidly recovered with no myocardial damage sustained </plain></SENT>
<SENT sid="7" pm="."><plain>An implantable cardioverter-defibrillator was placed for secondary prevention of <z:hpo ids='HP_0001699'>sudden death</z:hpo>, and <z:chebi fb="0" ids="31348">capecitabine</z:chebi> was implicated as the cause of <z:e sem="disease" ids="C0010073" disease_type="Disease or Syndrome" abbrv="">coronary vasospasm</z:e> which resulted in his presentation of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>To our knowledge, this is the first episode of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> as a consequence of suspected <z:chebi fb="0" ids="31348">capecitabine</z:chebi>-induced <z:e sem="disease" ids="C0010073" disease_type="Disease or Syndrome" abbrv="">coronary vasospasm</z:e> occurring at rest </plain></SENT>
<SENT sid="9" pm="."><plain>Our case highlights the potential for severe cardiotoxic consequences of <z:chebi fb="0" ids="31348">capecitabine</z:chebi> including <z:hpo ids='HP_0001699'>sudden death</z:hpo> from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>, and given the multi-disciplinary approach to managing <z:hpo ids='HP_0002664'>oncology</z:hpo> patients, health professionals should be aware of this </plain></SENT>
</text></document>